Can zapping a few tumor spots extend cancer treatment success?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Performance status 0 or 1 on the Eastern Cooperative Oncology Group (ECOG). 2. Histologically diagnosis of one of these tumour types: 1. Hormone receptor positive, HER2 negative breast cancer 2. Triple negative breast cancer 3. HER2+ breast cancer 4. Non small cell lung cancer without oncogenic addiction 5. Head and Neck squamous cell carcinoma without recurrence in the radiation field 6. Gastric adenocarcinoma 7. Esophageal cancer (adenocarcinoma or epidermoid carcinoma) 8. Recurrent pancreatic cancer without local recurrence 9. Anal cancer 10. Bladder cancer 11. Clear cells renal cell carcinoma 12. Prostate cancer sensitive to castration 13. Adenocarcinoma endometrial cancer 14. Epidermoid carcinoma or adenocarcinoma of the cervix 15. Colorectal cancer 16. Recurrent Soft Tissue Sarcoma 17. Melanoma 3. Patient with a decision by the local team to give OST and effective administration of OST. OST is defined as the most efficient choice in terms of survival in first line of advanced disease according to ESMO or other international guidelines. In case of multiple choice as first line, if no data provided direct evidence of superiority from one or the other options, there are all considered as OST. If the patient received a less efficient treatment because of his comorbidity or frailty, the eligible criteria won't be fulfilled. 4. Have non-progressive disease after 3 to 6 months of treatment, and less than 6 weeks before presentation to the multidisciplinary team 1. Patients with complete response and no target lesion are excluded. 2. Patients with bone metastasis with remaining bone condensation or scare from tumoral activity may be eligible depending on metabolic activity of the lesion or local multidisciplinary committee decision concerning the risk of residual disease. 5. After 3 to 6 months of treatment, and less than 6 weeks before start of LAT, patient must have an oligometastatic disease defined as all lesions (including primitive lesion) amenable to local ablative treatment according to local investigator team and respective local committee. Exclusion Criteria: 1. Patients who already received systemic antitumoral treatment in the advanced setting (including chemotherapy, immunotherapy, targeted therapy, …) 2. Patients without OST administration 3. Patients that have progressing lesion at any time point before decision of LAT by the expert committee 4. Has a known recent history of other invasive tumour, excepted if local investigator may provide histologically data that all active lesions targeted are from the same cancer primitive. 5. Radiotherapy or other LAT to any metastatic site before the start of OST. 6. Exclusion criteria specific for France: Vulnerable persons according to the article L.1121-6 of the public health law (CSP), adults who are the subject of a measure of legal protection or unable to express their consent according to article L.1121-8 of the CSP